Skip to content
DraconiticResearch
Search Sources API
181,713 studies31 sourcesUpdated 13 min ago
Peer-reviewedCC BYFrontiers in molecular biosciences

Lysosomal exoglycosidases as biomarkers of systemic diseases – what’s new?

  • Iwona Ptaszyńska-Sarosiek1
  • Weronika Wiktoria Sarosiek2
  • Gabriela Iga Sarosiek2
  • Anna Charuta3
  • Mateusz Maciejczyk4
4 affiliations
  1. 1Department of Forensic Medicine, Medical University of Bialystok , ,
  2. 2Independent Researcher , ,
  3. 3Institute of Health Sciences, Faculty of Medical and Health Sciences, University of Siedlce , ,
  4. 4Department of Hygiene, Epidemiology and Environmental Health President of the Polish Hygiene Society, Bialystok Branch, Medical University of Bialystok , ,
Read full textPDFDOICite

Abstract

Numerous studies suggest that lysosomal exoglycosidases can be utilised in the diagnosis and monitoring of various diseases. This paper summarises recent reports on the clinical use of N-acetyl-β-D-hexosaminidase (HEX), β-glucuronidase (GLU), β-galactosidase (GAL), α-mannosidase (MAN) and α-L-fucosidase (FUC) in systemic diseases. The clinical relevance of exoglycosidases has been demonstrated in liver disease, alcohol use disorder (AUD) in adults, nicotine addiction, kidney disease, cardiovascular disease, diabetes, cancer, nasopharyngeal disease and musculoskeletal disorders. Exoglycosidase activity correlates with disease severity and is characterised by high sensitivity, though low specificity. However, lysosomal exoglycosidases may have a particular application in addiction medicine. Compared to routine biomarkers, they are more sensitive and specific to alcohol-induced damage. Importantly, lysosomal exoglycosidases (especially HEX and its isoenzymes) show a greater correlation with acute ethanol exposure and are less dependent on individual factors (age, gender, comorbidities).

Related

  1. The pathological roles of intrinsically disordered proteins in lysosomal acidification dysfunction in neurodegenerative diseases.
    Kholoud Abd-ElRaouf, Dylan T Murphy, Lenny Yi Tong Cheong +2
    Translational neurodegenerationPeer-reviewedCC BYFull textPhysiologyEurope PMCPMC
  2. Hepatic retromer is essential for systemic cholesterol homeostasis by regulating lysosomal cholesterol handling
    Cristy R.C. Verzijl, Markus G. Barbosa, Dyonne Y. Vos +28
    Molecular MetabolismPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaPMC
  3. Associations of multiregional OCTA metrics and systemic hematologic biomarkers With 12-month diabetic retinopathy progression
    Lina Ge, Shenghai Huang, Weihe Zhou +4
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. High-frequency ultrasound-derived imaging biomarkers in inflammatory skin diseases
    Claudia Gonzalez, Cesar Gonzalez, Carolina Palacio +4
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Choriocapillaris Dysfunction in Retinal Diseases: Multimodal Imaging Biomarkers, Pathophysiological Insights, and Emerging Clinical Applications
    Feliciana Menna, Alessandro Meduri, Laura De Luca +3
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ptaszynskasarosiek2026lysosomal,
  title = {{Lysosomal exoglycosidases as biomarkers of systemic diseases – what’s new?}},
  author = {Iwona Ptaszyńska-Sarosiek and Weronika Wiktoria Sarosiek and Gabriela Iga Sarosiek and Anna Charuta and Mateusz Maciejczyk},
  journal = {Frontiers in molecular biosciences},
  year = {2026},
  month = oct,
  doi = {10.3389/fmolb.2026.1891977},
  url = {https://europepmc.org/article/PMC/PMC13720770},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Lysosomal exoglycosidases as biomarkers of systemic diseases – what’s new?
AU  - Iwona Ptaszyńska-Sarosiek
AU  - Weronika Wiktoria Sarosiek
AU  - Gabriela Iga Sarosiek
AU  - Anna Charuta
AU  - Mateusz Maciejczyk
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in molecular biosciences
DO  - 10.3389/fmolb.2026.1891977
UR  - https://europepmc.org/article/PMC/PMC13720770
AB  - Numerous studies suggest that lysosomal exoglycosidases can be utilised in the diagnosis and monitoring of various diseases. This paper summarises recent reports on the clinical use of N-acetyl-β-D-hexosaminidase (HEX), β-glucuronidase (GLU), β-galactosidase (GAL), α-mannosidase (MAN) and α-L-fucosidase (FUC) in systemic diseases. The clinical relevance of exoglycosidases has been demonstrated in liver disease, alcohol use disorder (AUD) in adults, nicotine addiction, kidney disease, cardiovascular disease, diabetes, cancer, nasopharyngeal disease and musculoskeletal disorders. Exoglycosidase activity correlates with disease severity and is characterised by high sensitivity, though low specificity. However, lysosomal exoglycosidases may have a particular application in addiction medicine. Compared to routine biomarkers, they are more sensitive and specific to alcohol-induced damage. Importantly, lysosomal exoglycosidases (especially HEX and its isoenzymes) show a greater correlation with acute ethanol exposure and are less dependent on individual factors (age, gender, comorbidities).
SN  - 2296-889X
ER  -